One of the health highlights mentioned in this update compiled by editors outlines the conclusions from a recent ISMP QuarterWatch report that examined many unanswered questions about the safety and effectiveness of pimavanserin (Nuplazid), a drug used to treat psychosis in Parkinson's patients, and called for stronger warnings on its label.
For the full text, visit U.S. News & World Report online.
More News
This article appeared on the Pharmacy Practice News website on April 17, 2019.
This article appeared on the Philadelphia Inquirer website on April 10, 2019.
This article appeared on the CNN website on March 28, 2019.